Please assess the completion status of the following clinical trial:

Trial Title: Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or above~* Diagnosed with CRC and prescribed with either XELOX for FOLFOX4 chemotherapy treatment~Exclusion Criteria:~* Patients less than 18 years of age~* Persons related unequally to investigators~* Patients who are mentally/cognitively disabled~* Patients who refuse to give consent to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFOX4 (Type: None): Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
- XELOX (Type: None): Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).